Abstract: The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes.

Abstract: The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres.

Abstract: Disclosed are: a novel dinoflagellate alga; and a macrolide compound which can be used as a novel anticancer agent. Specifically disclosed is a macrolide compound produced by a dinoflagellate Amphidinium sp. Strain HYA002 or HYA0024. The macrolide compound has excellent proliferation-inhibiting effect against a human tumor cell and therefore can be used as a novel anticancer agent.

Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Abstract: The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative.

Abstract: Organo-titanate catalysts are prepared that are useful to catalyze depolymerization of a polyester to produce macrocyclic oligoesters substantially free from macrocyclic co-oligoesters.

Abstract: A compound having a structure according to formula I wherein R1, R2, R3, R4, and R5 are as defined herein, are useful as kinase inhibitors.

Abstract: The present invention provides a novel method for producing a compound represented by formula (III) shown below, which comprises treating a compound represented by formula (I) shown below with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in a solvent in the presence of a ligand represented by formula (II) shown below, and the present invention further provides the novel compound represented by formula (I).

Abstract: The invention concerns compounds of formula (I), wherein —XmR1 and YnR2, identical or different are present, or one of the XmR1 or YnR2 is absent and YaR2, identical or different, is present, and in that case the bond between C1 and C2 is a double bond, XmR1 and YnR2 together represent a group A and in that case the bond between C1 and A is a double bond, or their pharmaceutically acceptable salts as medicine.

Abstract: The invention is to provide a novel polyhydroxyalkanoate having a reactive function group within the molecule and a producing method therefor In a polyhydroxyalkanoate containing a unit having a vinyl group in a side chain, such vinyl group is utilized for deriving a polyhydroxyalkanoate comprising a carboxyl group or a unit having an amide group and a sulfonic acid group.

Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.

Abstract: Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.

Abstract: The invention relates to the ether lactone of formula (I) which is characterized by interesting and original odor characteristics, which diffuses extremely well and is suitable for use as a fragrance, for example in cosmetic preparations, technical products or in alcoholic perfumery.

Abstract: Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.

Abstract: The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: The present disclosure relates to the preparation of ketal compounds from glycerol and levulinic acid and esters, and uses thereof.

Abstract: A composition of macrocyclic oligomer with at least one (meth)acrylate polymerizable group. A method includes preparing an activated precursor of an oligomer at pseudo high-dilution conditions. A method also includes preparing an activated precursor of an oligomer by reacting the precursor with an activated coupling agent, wherein the precursor is condensable and polymerizable.

Abstract: The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide sequence hybridising under conditions of high stringency to SEQ ID No. 35, to the complement of SEQ ID No. 35, or to a hybridisation probe derived from SEQ ID No. 35 or the complement thereof; or (e) a nucleotide sequence having at least 80% sequence identity with SEQ ID No. 35; or (f) a nucleotide sequence having at least 65% sequence identity with SEQ ID No. 35 wherein said sequence preferably encodes or is complementary to a sequence encoding a nystatin PKS enzyme or a part thereof.

Abstract: The invention is to provide a novel polyhydroxyalkanoate having a reactive function group within the molecule and a producing method therefor In a polyhydroxyalkanoate containing a unit having a vinyl group in a side chain, such vinyl group is utilized for deriving a polyhydroxyalkanoate comprising a carboxyl group or a unit having an amide group and a sulfonic acid group.

Abstract: A compound having a structure according to formula I wherein R1, R2, R3, R4, and R5 are as defined herein, are useful as kinase inhibitors.

Abstract: The present invention is a method for synthesizing macrosphelides represented by the following formula, and relates to the following method. The hydroxyl group of methyl 3-hydroxybutyrate is protected and reduced to alcohol. The alcohol is then oxidized to give 3-(tert-butyldimethylsilyloxy) butylaldehyde, and this aldehyde is then reacted with tert-butyl diethylphosphonoacetate to give an olefin, and then deprotected. Next, dehydrative condensation with diethylphosponoacetic acid are performed to give tert-butyl 5-[2-(diethylphosphonoyl) acetoxy] hex-2-enoate, and this compound is reacted with 3-(tert-butyldimethylsilyloxy) butylaldehyde to form a diester. Following this, deprotection is performed to give an alcohol, and dehydrative condensation of the alcohol with 3-(tert-butyldimethylsilyloxy) butyric acid gives a triester.

Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.

Abstract: Cyclohexane is reacted with hydrogen peroxide in the presence of nitric acid which is used as a catalyst in a suitable solvent for the production of trimeric cyclohexane peroxide.

Abstract: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.

Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.

Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.

Abstract: A polymeric compound for photoresist of the invention includes at least one monomer unit represented by following Formula (I): wherein R1, R2, R3, R4 and R5 are the same or different and are each a hydrogen atom or a methyl group; m, p and q each denote an integer of from 0 to 2; and n denotes 0 or 1, where the hydroxyl group and carbonyloxy group extending from a principle chain in the formula are independently combined with either of two carbon atoms on the far-left portion of the rings. By using the polymeric compound for photoresist as a base of a photoresist, the resulting photoresist exhibits well-rounded adhesion to substrates and resistance to etching.

Abstract: Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.

Abstract: The present invention provides compounds having improved stability over that of natural benzolactones, and a process for synthesizing these compounds. These compounds exhibit anti-cancer activity and inhibit V-ATPase activity.

Abstract: The invention relates to a process for the preparation of 15-pentadecanolide by hydrogenating 15-pentadecenolide and to its use.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. Exemplary novel compounds include those according to the formula: With respect the formula, G is selected from the group consisting of R2 substituents independently are selected from the group consisting of H and lower alkyl groups; Z is selected from the group consisting of the halogens and —CN; M is selected from the group consisting of O and NR3; R3 is selected from the group consisting of H, lower alkyl, R4CO, R4OCO, and R4SO2; R4 is selected from the group consisting of H, lower alkyl, and aryl; T is selected from the group consisting of CH2, CO, HCOH and protected derivatives thereof; W is H or OR; and X and Y independently are selected from the group consisting of O, NH, S, CO, and C.

Abstract: Methods for obtaining bryostatins from the marine bryozoans of the Bugula neritina species complex are provided wherein the methods involve the extraction and purification of bryostatins from the larvae of Bugula neritina organisms. Further, the present invention relates to a novel bryostatin composition that can be extracted from Bugula neritina.

Abstract: The invention concerns novel mikanolide derivatives, their preparation method and their therapeutic uses, in particular as anti-cancer and anti-viral agents.

Abstract: The object of the present invention is to provide a novel method for effectively producing a cyclic lactic acid oligomer, and a cyclic lactic acid oligomer produced by the method.

Abstract: The present invention provides (+)-Peloruside A and analogs thereof having microtubule-stabilizing activity, and a process for synthesizing these compounds. Also provided are intermediates and a process for synthesizing thereof. These compounds exhibit antiproliferative activity and are useful for treating cancer.

Abstract: Laulimalide compounds, intermediates thereto and methods for their preparation, and methods for their use in the treatment of diseases characterized by cellular hyperproliferation.

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

Abstract: An object of the present invention is to provide a novel method for the effective preparation of a mixture of linear and cyclic lactic acid oligomers.

Abstract: Heterocyclic aromatic amides (HAA) according to Formula I: wherein X1-X4, M, Z, and A are herein defined. The invention also encompasses hydrates, salts and complexes thereof. These compounds are useful as antifungal agents.

Abstract: A method of refining a crystal of a crude cyclic ester comprises the steps of supplying the crude cyclic ester to a vertically extending cylindrical refiner (1) from an inlet (3) provided at a lower part of the refiner (1), agitating the crude cyclic ester by an agitator provided in the refiner (1) to make the crude cyclic ester flow upwardly, refining the crystals of the crude cyclic ester by counterflow-contact between the upflowing crude cyclic ester and a downflowing melted liquid containing a refined crystal component, and taking out refined crystals of the crude cyclic ester from an outlet (4) provided at an upper part of the refiner (1).

Abstract: Laulimalide compounds, intermediates thereto and methods for their preparation, and methods for their use in the treatment of diseases characterized by cellular hyperproliferation.

Abstract: Methods for obtaining bryostatins from the marine bryozoans of the Bugula neritina species complex are provided wherein the methods involve the extraction and purification of bryostatins from the larvae of Bugula neritina organisms. Further, the present invention relates to a novel bryostatin composition that may be extracted by Bugula neritina.

Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.

Abstract: Cyclic ester oligomers (CEOs) are manufactured from linear polyesters or their precursors by a continuous reactive extraction in which the linear polyesters are converted to the CEOs and the CEOs selectively removed from the mixture by extraction with a fluid. The fluid may be a liquid or a gas. The CEOs prodcued are useful as monomers, for example in a reaction injection molding process to rapidly form polyesters from low viscosity liquids.

Abstract: Laulimalide and epothilone derivatives useful as microtubule stabilizing agents, and in the treatment of cancers are disclosed. Methods of making the compounds and using the compounds as therapeutic agents in treating cancers also are disclosed.

Abstract: Laulimalide compounds, intermediates thereto and methods for their preparation, and methods for their use in the treatment of diseases characterized by cellular hyperproliferation.

Abstract: The present invention provides a process for production of a cyclic ester by depolymerization of an aliphatic polyester. In the process, a mixture containing the aliphatic polyester and a specific polyalkylene glycol ether, which has a boiling point of 230-450° C. and a molecular weight of 150-450, is heated under normal or reduced pressure to a temperature at which depolymerization of the aliphatic polyester takes place. Then, a substantially homogeneous solution phase, consisting of the melt phase of the aliphatic polyester and the liquid phase of the polyalkylene glycol ether, is formed. Heating of the solution phase is continued to form the cyclic ester by depolymerization and distil out the cyclic ester together with the polyalkylene glycol ether, and then the cyclic ester is recovered from the distillate. The present invention also provides a process for purification of a crude cyclic ester by use of the specific polyalkylene glycol ether described above.

Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or imroved recognition domains are disclosed, including methods of preparing and utilizing the same.

Abstract: The present invention provides compounds having improved stability over that of natural benzolactones, and a process for synthesizing these compounds. These compounds exhibit anti-cancer activity and inhibit V-ATPase activity.

Abstract: A compound having the following formula: wherein R3 and M are defined herein, and processes therewith.